Irina Y. Adamova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irina Y. Adamova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina D. Ovchinnikova
National Medical Research Center of Cardiology Ministry of Health of the Russian Federation
1 shared publication - Elena A. Utkina
National Medical Research Center of Cardiology
1 shared publication - Oksana A. Dmitrieva
National Medical Research Center of Cardiology Ministry of Health of the Russian Federation
1 shared publication - Olga I. Afanasieva
Institute of Experimental Cardiology, National Medical Research Center of Cardiology n.a. acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow 121552, Russia
1 shared publication - Pavel Andreevich Levashov
Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russia
1 shared publication - Sergei N. Pokrovsky
Institute of Experimental Cardiology, National Medical Research Center of Cardiology n.a. acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow 121552, Russia
1 shared publication
Latest Publications
- Open Access
- 15 December 2021
- Published by Acta Naturae Ltd in Acta Naturae
- Vol. 13 (4) , 47-52
A Sorbent with Synthetic Ligand for Removing Pro-atherogenic and Pro-inflammatory Components from Human Blood Plasma
Elevated levels of apoB-100 containing lipoproteins and markers of systemic inflammation are often observed in patients with cardiovascular diseases. The concentrations can be reduced by pharmacotherapy or extracorporeal treatment. The sorbent, which removes CRP and atherogenic lipoproteins, simultaneously reduces the bloodstream concentration of these components. The efficacy and selectivity of the designed sorbent were studied, desorption constants of CRP (Kd = 4.2 10-8 M) and LDL (Kd = 7.7 10-7 M) were distribution coefficients of CRP (Kc = 101) and Lp(a) (Kc = 38) were calculated, and the ability to bind large amounts of atherogenic lipoproteins (up to 32 mg of TC per mL of the sorbent gel) was demonstrated. Our sorbent can be recommended for performing complex removal of CRP and atherogenic lipoproteins from the blood plasma in patients with refractory hyperlipidemia and CVD that are accompanied by elevated levels of CRP.
- 15 December 2021
- Published by Acta Naturae Ltd in Acta Naturae
- Vol. 13 (4) , 47-52
Open AccessA Sorbent with Synthetic Ligand for Removing Pro-atherogenic and Pro-inflammatory Components from Human Blood Plasma
Elevated levels of apoB-100 containing lipoproteins and markers of systemic inflammation are often observed in patients with cardiovascular diseases. The concentrations can be reduced by pharmacotherapy or extracorporeal treatment. The sorbent, which removes CRP and atherogenic lipoproteins, simultaneously reduces the bloodstream concentration of these components. The efficacy and selectivity of the designed sorbent were studied, desorption constants of CRP (Kd = 4.2 10-8 M) and LDL (Kd = 7.7 10-7 M) were distribution coefficients of CRP (Kc = 101) and Lp(a) (Kc = 38) were calculated, and the ability to bind large amounts of atherogenic lipoproteins (up to 32 mg of TC per mL of the sorbent gel) was demonstrated. Our sorbent can be recommended for performing complex removal of CRP and atherogenic lipoproteins from the blood plasma in patients with refractory hyperlipidemia and CVD that are accompanied by elevated levels of CRP.